Integrated Filing — IndAS



General information about company

Scrip Code 532649
NSE Symbol NECLIFE
MSEI Symbol NOTLISTED
ISIN INE023H01027
Name of company Nectar Lifesciences Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 30-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 25-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceutical Business Segment
Start date and time of board meeting 30-05-2026   12:30:00
End date and time of board meeting 30-05-2026   14:20:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 0.00 0.00
Other income 758.00 929.09
Total income 758.00 929.09
2 Expenses
(a) Cost of materials consumed 0.00 0.00
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 126.22 191.22
(e) Finance costs 590.05 3,612.52
(f) Depreciation, depletion and amortisation expense 8.28 34.26
(f) Other Expenses
1 Other Expenses 5,726.31 5,878.98
Total other expenses 5,726.31 5,878.98
Total expenses 6,450.86 9,716.98
3 Total profit before exceptional items and tax (5,692.86) (8,787.89)
4 Exceptional items 0.00 0.00
5 Total profit before tax (5,692.86) (8,787.89)
6 Tax expense
7 Current tax 0.00 0.00
8 Deferred tax (1,971.64) (3,053.16)
9 Total tax expenses (1,971.64) (3,053.16)
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (3,721.22) (5,734.73)
12 Profit (loss) from discontinued operations before tax (7,320.58) (37,428.19)
13 Tax expense of discontinued operations (4,249.38) (13,873.82)
14 Net profit (loss) from discontinued operation after tax (3,071.20) (23,554.37)
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period (6,792.42) (29,289.10)
17 Other comprehensive income net of taxes 7.93 7.94
18 Total Comprehensive Income for the period (6,784.49) (29,281.16)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,942.61 1,942.61
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 0.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -1.85 -2.62
Diluted earnings (loss) per share from continuing operations -1.85 -2.62
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations -1.53 -10.78
Diluted earnings (loss) per share from discontinued operations -1.53 -10.78
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -3.38 -13.4
Diluted earnings (loss) per share from continuing and discontinued operations -3.38 -13.4
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above financial results were reviewed by Audit Committee on May 30, 2026, and approved by the Board of Directors (“Board”) in its meeting held on May 30, 2026, and Audited by the Statutory Auditors of the Company. The auditor's reports are attached along with these results. The Board hereby declares that audit reports do not contain any modified opinion. 2. The Company is exclusively in the pharmaceutical business segment. 3. The Statement of Assets and Liability is attached as Annexure 1. 4. The Statement of Cash Flow is attached as Annexure 2. 5. Previous period’s figures have been regrouped and reclassified wherever necessary to make them comparable with current period. 6. The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figure in respect of the full financial year ended March 31 and the unaudited published year to date figures upto the third quarter ended December 31 which was subject to limited review. 7. The Company has two wholly owned subsidiaries with the following details: - a) Neclife PT, Unipessoal LDA, remained inoperative during the year ended March 31, 2026. b) Avensis Exports Private Limited (“AEPL”), which was acquired effective March 6, 2026. 8. The Company is Not a Large Corporate as per the framework provided in the SEBI Circular dated October 19, 2023 on Fund raising by issuance of debt securities by Large Entities. 9. Going Concern During the year, the Company sold a substantial part of its existing business operations by way of slump sale and incurred losses. The transaction has resulted in significant liquidity, and the Company, after discharging all its debts, continues to possess adequate cash and liquid resources to meet its obligations, if any. Further, the Company has amended its object clause to undertake activities in the real estate sector and is currently evaluating the various projects under the revised business framework. In furtherance of this objective, the Company has also acquired AEPL as its wholly owned subsidiary. Considering the Company’s solvent financial position and availability of funds, the Board believes that the Company will continue to operate as a going concern for the foreseeable future. Accordingly, the financial results have been prepared on a going concern basis. 10. Material Transactions A. Discontinued Operations a. Pharma Business Pursuant to the Business Transfer Agreement (“BTA”) dated July 7, 2025, the Company transferred its Active Pharmaceutical Ingredients business located at Unit 1 and Unit 2, Derabassi, Punjab, and its Formulation business located at Unit 6, Baddi, Himachal Pradesh (collectively referred to as the “Pharma Businesses”) to Ceph Lifesciences Private Limited (“Ceph”) on a going concern basis through a slump sale, which was completed on November 10, 2025. The transaction was undertaken for an aggregate consideration of INR127,000.00 lakhs, which, after adjustments for working capital in accordance with the BTA, was finalized at a consolidated consideration of INR125,398.55 lakhs. Out of the above amount, the Company has received INR118,798.55 lakhs up to March 31, 2026, and the balance of INR6,600.00 lakhs is receivable as at the year end. A resultant profit of INR16,337.33 lakhs arising from the sale of the Pharma Businesses has been recognised under Exceptional Items. b. Menthol Assets Pursuant to the Asset Purchase Agreement (“APA”) dated July 7, 2025, the Company transferred the assets relating to its menthol business (“Menthol Assets”) to Ceph on November 10, 2025, for a consideration of INR2,000.00 lakhs, and received the entire consideration. B. Assets Classified as Held for Sale a. Capsule Business (EHGC) The Company has entered into a Business Transfer Agreement (“Capsule BTA”) dated December 20, 2025, with Capnest Health Care Private Limited (“Capnest”) for the slump sale of its Empty Hard Gelatin Capsule business located at Village Bhatoli Kalan, Pargana Dharmpur, Tehsil Baddi, District Solan, Himachal Pradesh (“Capsule Business”), on a going concern basis, for a consideration of INR1,990.00 lakhs, including transfer of related receivables and payables/creditors, subject to working capital adjustments specified in the Capsule BTA and approval under Section 118 of the Himachal Pradesh Tenancy and Land Reforms Act, 1972. The transaction shall be completed in accordance with the terms set out in the Capsule BTA. b. Other Assets The Company is also evaluating the monetization of the following assets with the objective of optimizing non-core assets and further strengthening its liquidity position: (i) Jammu Unit: Fixed assets pertaining to the Company’s Jammu unit, which has remained inoperative. Necessary steps in relation to the proposed transaction have been initiated. (ii) Land near Garhshankar, Punjab: Vacant land situated near Garhshankar, Punjab. A portion of the said land has already been sold subsequent to the financial year end, indicating progress in the Company’s planned disposal strategy. Accordingly, the results relating to the above disposed businesses/assets have been disclosed as discontinued operations in accordance with Ind AS 105. Further, in the audited standalone financial results, the net results of “Pharma Businesses”, “Menthol Assets” and “Capsule Business” has been disclosed separately as discontinued operation as required by Indian Accounting Standard (Ind AS) 105 – Asset Held for Sale and Discontinued Operations and Schedule Ill to the Companies Act, 2013. Consequently, the Company's Statement of Profit and Loss for the year ended March 31, 2026, pertains to its continuing operations only and for that purpose the results for the other reporting periods i.e., December 31, 2025, and March 31, 2026, have been restated accordingly. Standalone Operations relating to the Pharma Businesses, Menthol Assets and “Capsule Business” in respect of total income, total expenses and tax are being disclosed separately as Discontinued operations as part of the results below: INR in lakhs S. No. Particulars Quarter Ended Year Ended 31-Mar-26 31-Dec-25 31-Mar-25 31-Mar-26 31-Mar-25 Audited Unaudited Audited Audited Audited 1 Revenue from operations 571.35 2,173.55 42,890.76 40,138.43 1,66,997.36 2 Other income 0.18 1,214.40 168.13 1,221.82 311.38 3 Total expenses 7,892.12 13,045.21 61,809.06 95,125.77 1,83,569.34 4 Profit before tax (7,320.58) (9,657.26) (18,750.17) (53,765.51) (16,260.60) 5 Exceptional item (Gain on slump sale) - 16,337.32 - 16,337.32 - 6 Tax expenses (4,249.38) 3,200.55 (5,751.87 (13,873.82) (4,822.78) 7 Net profit after tax (3,071.20) 3,479.51 (12,998.30 (23,554.37) (11,437.82) 11. Buy-back of Equity Shares Based on the Board’s approval at its meeting held on December 03, 2025, the Company undertook a buy-back of up to 3,00,00,000 fully paid-up equity shares of INR1 each at INR27.00 per share, aggregating INR8,100.00 lakhs, representing approximately 13.38% of the Company’s paid-up equity share capital as at March 31, 2025, through the tender offer route on a proportionate basis from eligible equity shareholders, excluding the Promoters and Promoter Group, in accordance with Sections 68, 69 and 70 of the Companies Act, 2013 (“Act”) and the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended. The buy-back was open from December 31, 2025 to January 06, 2026. The consideration was paid by the Company on January 13, 2026, and the 3,00,00,000 equity shares were extinguished by the National Securities Depository Limited on January 20, 2026. Consequent to the buy-back, the paid-up equity share capital of the Company was reduced by INR300.00 lakhs, with the premium of INR7,800.00 lakhs adjusted against the Securities Premium Account and INR300.00 lakhs transferred to the Capital Redemption Reserve in accordance with Section 69 of the Companies Act, 2013. 12. Pursuant to the approvals granted by the Board, the Company deployed certain surplus funds in mutual fund, ETF and equity instruments during the year. Subsequently, volatility in the financial markets arising from prevailing market conditions and geopolitical developments adversely impacted the value of such investments, resulting in a loss of INR 5,209.53 lakhs. The resultant impact has been recognized in the Statement of Profit and Loss in accordance with Ind AS 109 – Financial Instruments. 13. Extraordinary and Exceptional items – Refer Note 10.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 10,340.49
Capital work-in-progress 0.00
Investment property 0.00
Goodwill 111.24
Other intangible assets 0.00
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 23.51
Trade receivables, non-current 0.00
Loans, non-current 7.00
Other non-current financial assets
1 Other non-current financial assets 292.84
Total of other non-current financial assets 292.84
Total non-current financial assets 323.35
Deferred tax assets (net) 22,447.76
Other non-current assets
1 Other non-current assets 55.58
Total of other non-current assets 55.58
Total non-current assets 33,278.42
2 Current assets
Inventories 29.82
Current financial asset
Current investments 1,297.08
Trade receivables, current 0.00
Cash and cash equivalents 0.00
Bank balance other than cash and cash equivalents 11,213.48
Loans, current 9.13
Other current financial assets
Total of other current financial assets 6,599.99
Total current financial assets 19,119.68
Current tax assets (net)
Other current assets
1 Other current assets 6,147.33
Total of other current assets 6,147.33
Total current assets 25,296.83
3 Non-current assets classified as held for sale 3,585.39
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 62,160.64
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,942.61
Other equity 56,286.93
Total equity attributable to owners of parent 58,229.54
Non controlling interest
Total equity 58,229.54
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other non-current financial liabilities 919.17
Total of other non-current financial liabilities 919.17
Total non-current financial liabilities 919.17
Provisions, non-current 0.49
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 919.66
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other current financial liabilities
1 Other current financial liabilities 2,571.23
Total of other current financial liabilities 2,571.23
Total current financial liabilities 2,571.23
Other current liabilities 33.08
1 Other current liabilities 33.08
Total of other current liabilities 33.08
Provisions, current 0.71
Current tax liabilities (Net) 0.00
Deferred government grants, Current 0.00
Total current liabilities 2,605.02
3 Liabilities directly associated with assets in disposal group classified as held for sale 406.42
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 3,931.10
Total equity and liabilites 62,160.64
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of the net defined benefit liability/asset 12.18 12.18
Total Amount of items that will not be reclassified to profit and loss 12.18 12.18
2 Income tax relating to items that will not be reclassified to profit or loss 4.26 4.26
3 Amount of items that will be reclassified to profit and loss
1 Foreign Exchange Translation Reserve (Net of Tax) 0.02 0.03
Total Amount of items that will be reclassified to profit and loss 0.02 0.03
4 Income tax relating to items that will be reclassified to profit or loss 0.01 0.01
5 Total Other comprehensive income 7.93 7.94



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax (8,787.89)
Adjustments for reconcile profit (loss)
Adjustments for finance costs 3,612.52
Adjustments for decrease (increase) in inventories 23,292.44
Adjustments for decrease (increase) in trade receivables, current 1,664.61
Adjustments for decrease (increase) in trade receivables, non-current 29,930.86
Adjustments for decrease (increase) in other current assets 11,220.20
Adjustments for decrease (increase) in other non-current assets 161.77
Adjustments for other financial assets, non-current 79.88
Adjustments for other financial assets, current (5,665.18)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (34,170.37)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (809.64)
Adjustments for increase (decrease) in other non-current liabilities (72.08)
Adjustments for depreciation and amortisation expense 2,280.31
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (291.50)
Adjustments for provisions, non-current (1,859.07)
Adjustments for other financial liabilities, current (5,037.60)
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.04
Adjustments for interest income 703.98
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 20,372.93
Other adjustments to reconcile profit (loss) (70,090.62)
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (26,084.56)
Net cash flows from (used in) operations (34,872.45)
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (34,872.45)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 2,045.76
Purchase of property, plant and equipment 1,227.42
Proceeds from sales of investment property 33,441.16
Purchase of investment property 39,894.89
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.04
Interest received 703.98
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 1,25,746.26
Net cash flows from (used in) investing activities 1,20,814.89
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 8,100.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 64,875.34
Payments of lease liabilities 63.26
Dividends paid 0.00
Interest paid 3,612.52
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (76,651.12)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 9,291.32
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 9,291.32
Cash and cash equivalents cash flow statement at beginning of period 1,922.16
Cash and cash equivalents cash flow statement at end of period 11,213.48





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Deepak Jindal & Co. Yes 31-05-2027